{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:15:38Z","timestamp":1783736138215,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jid.2024.08.015","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T13:55:19Z","timestamp":1727099719000},"page":"9-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cutaneous T-Cell Lymphoma and Dupilumab Use: A Multifactorial and Complex Story"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1229","authenticated-orcid":false,"given":"Marie","family":"Beylot-Barry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-4212","authenticated-orcid":false,"given":"Delphine","family":"Staumont-Salle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2024.08.015_bib1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","article-title":"Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study","volume":"160","author":"Beck","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.08.015_bib2","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jamadermatol.2023.3849","article-title":"Dupilumab-associated lymphoid reactions in patients with atopic dermatitis","volume":"159","author":"Boesjes","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.08.015_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.08.015_bib4","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jid.2024.08.015_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaad.2024.03.039","article-title":"Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study","volume":"91","author":"Hasan","year":"2024","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.08.015_bib6","first-page":"211","article-title":"Cutaneous T-cell lymphoma following dupilumab use: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)","volume":"144","author":"Lavin","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.08.015_bib7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/ijd.16388","article-title":"Cutaneous T-cell lymphoma following dupilumab use: a systematic review","volume":"62","author":"Park","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2024.08.015_bib8","article-title":"Cutaneous T-cell lymphoma and dupilumab use: a retrospective matched cohort study of clinical characteristics and treatment outcomes [e-pub ahead of print]","author":"Stuver","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.08.015_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jdcr.2021.05.037","article-title":"Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash","volume":"14","author":"Trum","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2024.08.015_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/bjd\/ljad072","article-title":"Malignancy risk in patients with atopic dermatitis: a population-based cohort study [published correction appears in Br J Dermatol 2024;190:e49]","volume":"189","author":"Wan","year":"2023","journal-title":"Br J Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24020839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24020839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T03:37:52Z","timestamp":1767238672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X24020839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0022202X24020839"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2024.08.015","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous T-Cell Lymphoma and Dupilumab Use: A Multifactorial and Complex Story","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2024.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2024.06.1272","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Society for Investigative Dermatology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}